A detailed history of Harbour Investments, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Harbour Investments, Inc. holds 341 shares of VRTX stock, worth $158,414. This represents 0.01% of its overall portfolio holdings.

Number of Shares
341
Previous 385 11.43%
Holding current value
$158,414
Previous $180,000 12.22%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$460.0 - $505.78 $20,240 - $22,254
-44 Reduced 11.43%
341 $158,000
Q2 2024

Jul 26, 2024

BUY
$392.81 - $485.53 $5,892 - $7,282
15 Added 4.05%
385 $180,000
Q1 2024

Jul 22, 2024

BUY
$407.69 - $446.08 $23,238 - $25,426
57 Added 18.21%
370 $154,000
Q4 2023

Feb 16, 2024

BUY
$343.0 - $410.68 $17,493 - $20,944
51 Added 19.47%
313 $127,000
Q3 2023

Nov 15, 2023

SELL
$338.18 - $362.46 $4,396 - $4,711
-13 Reduced 4.73%
262 $91,000
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $1,886 - $2,111
6 Added 2.23%
275 $96,000
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $18,409 - $21,001
-65 Reduced 19.46%
269 $84,000
Q4 2022

Feb 15, 2023

BUY
$285.76 - $321.48 $12,859 - $14,466
45 Added 15.57%
334 $96,000
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $36,418 - $45,345
-155 Reduced 34.91%
289 $81,000
Q4 2021

Feb 16, 2022

SELL
$177.01 - $223.45 $148,334 - $187,251
-838 Reduced 65.37%
444 $98,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $26,845 - $30,042
148 Added 13.05%
1,282 $233,000
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $19,123 - $22,552
102 Added 9.88%
1,134 $229,000
Q1 2021

Aug 17, 2021

BUY
$207.02 - $241.31 $213,023 - $248,307
1,029 Added 34300.0%
1,032 $222,000
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $621 - $723
3 New
3 $1,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.